<DOC>
	<DOCNO>NCT02684370</DOCNO>
	<brief_summary>This randomize double blind , double dummy , placebo active comparator control , parallel design study perform assess safety efficacy BI 655066/ABBV-066 ( risankizumab ) support registration treatment moderate severe chronic plaque psoriasis adult patient .</brief_summary>
	<brief_title>BI 655066 ( Risankizumab ) Compared Placebo Active Comparator ( Ustekinumab ) Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Inclusion criterion : Male female patient age &gt; = 18 year screen . Have diagnosis chronic plaque psoriasis ( without psoriatic arthritis ) least 6 month first administration study drug . Have stable moderate severe chronic plaque psoriasis without psoriatic arthritis Screening Baseline ( Randomisation ) : Have involve body surface area ( BSA ) &gt; = 10 % Have Psoriasis Area Severity Index ( PASI ) score &gt; = 12 Have static Physician Global Assessment ( sPGA ) score &gt; = 3 . Must candidate systemic therapy phototherapy psoriasis treatment , assess investigator . Must candidate treatment Stelara® ( ustekinumab ) accord local label . Exclusion criterion : Patients : 1. nonplaque form psoriasis ( include guttate , erythrodermic , pustular ) 2. current druginduced psoriasis ( include exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) 3. active ongoing inflammatory disease psoriasis psoriatic arthritis might confound trial evaluation accord investigator 's judgment Previous exposure BI 655066 . Previous exposure ustekinumab ( Stelara® ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Skin Diseases , Papulosquamous</keyword>
	<keyword>ustekinumab</keyword>
	<keyword>Dermatologic Agents</keyword>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>